NEW DELHI. The government has approved the strategic disinvestment of Mini Ratna PSU Indian Medicines Pharmaceutical Corporation Limited (IMPCL), with Skymap Pharmaceuticals emerging as the successful bidder at ₹121.01 crore. The approval was granted by the Alternative Mechanism (AM), an empowered ministerial committee, paving the way for the transfer of 100% equity shareholding and complete management control of IMPCL to the private company. The move marks the government’s total exit from the entity and forms part of the Department of Investment and Public Asset Management’s (DIPAM) strategy to modernize the traditional medicine sector. Under private ownership, IMPCL is expected to accelerate research and development, align Ayush medicines with global pharmaceutical standards, and modernize its manufacturing infrastructure, including the Mohan plant, through advanced technologies and faster decision-making processes.
Government Approves Strategic Sale of IMPCL to Skymap Pharmaceuticals for ₹121.01 Crore
